| Previous Close | 0.5200 |
| Open | 0.5300 |
| Bid | 0.5100 x N/A |
| Ask | 0.5300 x N/A |
| Day's Range | 0.5200 - 0.5400 |
| 52 Week Range | 0.3500 - 0.7900 |
| Volume | 20,000 |
| Avg. Volume | 58,541 |
| Market Cap | 34.083M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0390 |
| Earnings Date | Aug. 20, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: Nanalysis Scientific Corp.
Approved on July 1 the granting of 40,000 restricted share units to each director of the Company pursuant ...
CNW GroupNanalysis Scientific Corp. Announces Grant of Restricted Share Units
CALGARY, AB , July 2, 2020 /CNW/ - Nanalysis Scientific Corp. ("Nanalysis" or the "Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1) is pleased to announce that the Board of Directors ...
CNW GroupNanalysis Scientific Corp. Reports First Quarter 2020 Results
RS2D also expands the Company's product portfolio with its Pulse console for high-field NMR systems. Full integration of the companies has been completed, highlighted by two RS2D executives taking important leadership positions: Remy Schimpf as Senior VP of Sales, and Julien Muller as Chief Technology Officer. For the three months ended March 31, 2020, the Company reported consolidated revenue of $1,523k, a decrease of $542k over the $2,065k for the comparable period ended March 31, 2019.
